Podcasts about nadim

Nadim was a successful entrepreneur, happily married, and with two wonderful children. But the dream life was shattered when he took his daughter Natasha and her best friend on holiday to France. Tragically, Natasha had an anaphylactic reaction shortly after takeoff after ingesting sesame seeds in her sandwich, from which she never recovered. Subsequently, Nadim and his wife Tanya founded the Natasha Allergy Research Foundation, and their campaigning - for which they were both awarded an OBE by the Queen - has led to changes in the law. Nadim's journey to faith through this horrendous experience is deeply touching, and God has opened doors of real influence and opportunity for him to witness gently to the Prince of Peace in many different contexts. I spent much of this interview in tears, so it's a different flavour from previous episodes, but deeply moving and inspiring.Do check out www.narf.org.ukAnd you can contact Nadim at nadim.el[@]narf.org.uk ---Order the Inspired Book nowSupport our work in Burundi: greatlakesoutreach.org/inspired ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---Follow us on Instagram: @inspiredwith.sgWeekly episode WhatsApp link: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠greatlakesoutreach.org/whatsappWeekly email notification: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠greatlakesoutreach.org/inspiredemail⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more from Simon, visit: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠simonguillebaud.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠---Produced by Great Lakes Outreach - Transforming Burundi & Beyond: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠greatlakesoutreach.org⁠⁠⁠⁠⁠

What if the key to raising happier kids was actually the secret to becoming happier yourself? Discover the ingredients of happiness with Nadim Saad, author of "The Happy, Confident Me" and founder of the Happy Confident Company. Learn how to foster better connections, manage emotions, and create a positive family dynamic that benefits both parents and children.Join Matt and Nadim as they explore practical strategies for cultivating happiness, from understanding your feelings to reframing negative thoughts. Uncover the power of introspection, gratitude, and compassion in transforming your family's emotional landscape. Whether you're a parent looking to raise confident children or an individual seeking personal growth, this episode will equip you to create a happier, more fulfilling life.0:00 Introduction5:42 Connection to self: The foundation of happiness11:31 Reframing thoughts to change feelings17:35 The power of feeling safe, loved, and valued24:04 Embracing vulnerability and shared human experiences28:23 Optimism and gratitude as happiness ingredients32:10 Practical tools for cultivating happiness in families35:06 Fostering emotional intelligence in parent-child relationships36:31 Five key takeaways for a happier lifeAbout the GuestNadim Saad is the author of "The Happy, Confident Me" and founder of the Happy Confident company. His work and tools are helping children learn the ingredients of happiness at schools worldwide. Nadim has spoken on raising happy, confident children at companies like Google and JP Morgan, and is dedicated to transforming family dynamics through positive parenting techniques and emotional intelligence education.Resources Mentioned:

Interview avec Omar & Nadim, les deux fondateurs du collectif Blind qui organise des événements dans le monde entier et à Strasbourg.Réalisé en direct sur RBS le 09/04/25 avec Pierre Liermann

On this episode, we speak with Lebanese economist and political analyst Nadim Shehadi. Can the new president deliver on his promises of reform and economic revival? Or will the persistent influence of Hezbollah, permanently hinder his chances of success? Plus, we examine America's evolving role in the country and explore whether normalization with Israel could be on the cards.

Dans cet épisode spécial Podcasthon, on s'attaque à une question brûlante : le numérique tient-il vraiment ses promesses en matière d'égalité des chances ? Pour en parler, un duo de choc : Matthieu Stéphani, entrepreneur et maestro du podcast, et Nadim Bel Lallahom, président de Diversidays et ardent défenseur d'une tech plus inclusive.Reproduction sociale, biais, discriminations… Le numérique est-il une opportunité en or ou un miroir des inégalités ? On en débat sans langue de bois, avec la conviction que l'innovation ne vaut que si elle profite à tous.

A weekend break in Atlantis sees Ziyad getting drawn into un-masculine like pursuits; and Sabha reveals the shocking truth about Nadim to Mansoor in the drama: Reversing the Roles.

Aujourd'hui dans Parlons-en, nous prenons le temps de revenir sur ce qu'il s'est passé depuis une semaine en Syrie. Une semaine marquée par les pires massacres d'Alaouites et par l'espoir d'un accord avec les Kurdes, qui ont montré à quel point le chemin vers l'unité et la réconciliation est long, après un demi siècle de dictature.

Nadim Shehadi returns to The Beirut Banyan. In this episode we discuss the 2020 Eurobond default and the controversy surrounding that decision. We also look at fault lines formed between the banking sector and restructuring-advocacy groups and the wider story of the economic direction of the country. Nadim Shehadi is an economist and regular contributor to Arab News. The podcast is only made possible through listener and viewer donations. Please help support The Beirut Banyan by contributing via PayPal: https://www.paypal.me/walkbeirut Or donating through our Patreon page: https://www.patreon.com/thebeirutbanyan Subscribe to our YouTube channel and your preferred audio platform. Follow us on Facebook, Instagram & Twitter: @thebeirutbanyan And check out our website: www.beirutbanyan.com Timestamps: 0:00 Intro 0:47 The bigger story 2:58 Any banking sector 5:39 Individual action 12:45 Default 18:49 Fault line 24:08 The banks 33:11 A clear dichotomy 36:04 The Central Bank 43:23 The real question

Über den Eklat zwischen dem ukrainischen Präsidenten Selenski und US-Präsident Donald Trump im Oval Office, der kurzerhand das Narrativ im Ukrainekrieg ausgetauscht hat, sprachen wir mit Nadim, Renate Dillmann und Arian Schiffer-Nasserie. Grobe Gesprächsübersicht: 1. Die Debatte im Weißen Haus – Weltgeschichte vor laufenden Kameras! Um was ging es? Wie kam es zum Streit? 2. Warum wurde das nicht hinter verschlossenen Türen abgehandelt? Jeweilige Berechnungen der Kontrahenten Bedeutung des Streits um „Narrative“ a) bezüglich demokratischer Öffentlichkeit 3. Vorläufige Ergebnisse a) USA b) Ukraine c) Euros/GB (Einbezug der Besuche von Macron und Starmer) Was noch zu besprechen bleibt sind genauere Kriegsziele und die Rolle der USA in der Weltordnung. Wir sind 99 ZU EINS! Ein Podcast mit Kommentaren zu aktuellen Geschehnissen, sowie Analysen und Interviews zu den wichtigsten politischen Aufgaben unserer Zeit.#leftisbest #linksbringts #machsmitlinks Wir brauchen eure Hilfe! So könnt ihr uns unterstützen: 1. Bitte abonniert unseren Kanal und liked unsere Videos. 2. Teil unseren content auf social media und folgt uns auch auf Twitter, Instagram und FB 3. Wenn ihr Zugang zu unserer Discord-Community, sowie exklusive After-Show Episoden und Einladungen in unsere Livestreams bekommen wollt, dann unterstützt uns doch bitte auf Patreon: www.patreon.com/99zueins 4. Wir empfangen auch Spenden unter: https://www.paypal.com/donate/?hostedbuttonid=NSABEZ5567QZE

This episode of Reversing the Roles sees Ziyad not fulfilling his role as househusband. Rumana, Sabha's daughter from her first marriage finds out the dark truth about her real father, Nadim.

Heute geht es um das Thema Radikalisierung und wie man sie verhindern kann. Dazu habe ich mich mit Nadim Mazarweh, Leiter der Kontaktstelle für Extremismusprävention und Deradikalisierung der Islamischen Glaubensgemeinschaft in Österreich, in seinem Büro in Wien getroffen. In dem Gespräch sprechen wir über den Täter von Villach und was es für eine effektive Extremismusprävention und Deradikalisierung braucht. Infos zum Thema: https://www.derislam.at/kontaktstelle-fuer-extremismuspraevention-und-deradikalisierung/?fbclid=IwY2xjawIhylVleHRuA2FlbQIxMAABHXKFrEYZ8oCPNXIKa5I52VRIryfu37ZFr4tJmtesYKeBwnJaL5TwdsQ7LA_aem__Ubv26KKUTf-qrodDlHahw

2025 - 03 - 03 Professor Nadim Darwish by CurtinFM 100.1 in Perth, Western Australia

Zusammen mit Nico rede ich über den bisherigen Abschluss der Daredevil Serie, bevor Daredevil Born Again bei Disney plus startet!!!

Rozmowa w związku z 11. rocznicą protestów Tatarów krymskich w Symferopolu przeciwko aneksji Krymu przez Rosję. Gośćmi  są również: Halil Halilow i Barbara Kaczmarczyk z Domu Krymskiego.

"Du hast etwas gegen Kriegsverbrechen? Dann ist regulärer Krieg für dich wohl in Ordnung." Inge und Nadim diskutieren über Sinn und Unsinn eines Argumentationsmusters, das Kritik an Abweichungen mit dem Hinweis auf eine schlimme Normalität zurückweisen will. Wir sind 99 ZU EINS! Ein Podcast mit Kommentaren zu aktuellen Geschehnissen, sowie Analysen und Interviews zu den wichtigsten politischen Aufgaben unserer Zeit.#leftisbest #linksbringts #machsmitlinks Wir brauchen eure Hilfe! So könnt ihr uns unterstützen: 1. Bitte abonniert unseren Kanal und liked unsere Videos. 2. Teil unseren content auf social media und folgt uns auch auf Twitter, Instagram und FB 3. Wenn ihr Zugang zu unserer Discord-Community, sowie exklusive After-Show Episoden und Einladungen in unsere Livestreams bekommen wollt, dann unterstützt uns doch bitte auf Patreon: www.patreon.com/99zueins 4. Wir empfangen auch Spenden unter: https://www.paypal.com/donate/?hostedbuttonid=NSABEZ5567QZE

Jak fungují běžné digitální nástroje, které každý den používáme? Na jakých principech pracuje obyčejný mobil nebo internetová stránka? Kolik toho o nich vlastně víme? I to jsou otázky, které britský kurátor Nadim Samman klade na velkorysé mezinárodní výstavě Poetics of Encryption. Do jednoho prostoru v ní svedl digitální díla více než tří desítek umělců a umělkyň z celého světa. Pozornost už vyvolala v Berlíně a Kodani, teď ji můžete vidět v Galerii Rudolfinum v Praze.Všechny díly podcastu Mozaika můžete pohodlně poslouchat v mobilní aplikaci mujRozhlas pro Android a iOS nebo na webu mujRozhlas.cz.

Jak fungují běžné digitální nástroje, které každý den používáme? Na jakých principech pracuje obyčejný mobil nebo internetová stránka? Kolik toho o nich vlastně víme? I to jsou otázky, které britský kurátor Nadim Samman klade na velkorysé mezinárodní výstavě Poetics of Encryption. Do jednoho prostoru v ní svedl digitální díla více než tří desítek umělců a umělkyň z celého světa. Pozornost už vyvolala v Berlíně a Kodani, teď ji můžete vidět v Galerii Rudolfinum v Praze.

Conversa com Nadim Donato sobre o comércio mineiro.

Hey, Brave Table fam! This week, I'm sitting down with my dear soul brother, Nadim Saad, to dive into the ultimate parenting upgrade! Nadim is a serial entrepreneur, conscious parenting pioneer, and founder of the Happy Confident Company, which is changing the way children learn emotional intelligence and agency. Whether you're a mom, dad, or future parent, this episode is packed with revolutionary tools and strategies to help you raise happy, confident, and emotionally resilient children—while healing yourself in the process. We discuss everything from breaking the cycles of immigrant parenting to leadership lessons that translate beautifully into the home. Let's just say, this conversation will leave you inspired, empowered, and ready to step into your best parenting self. Oh, and if you're wondering how to tackle sibling rivalry, the infamous 1-2-3 method, or what to do when other caregivers don't parent like you, we've got you covered! What you'll get out of this episode…  Parenting and leadership guide through example, listening, and vision. Offering kids limited, meaningful choices fosters agency and eases anxiety. Repairing mistakes builds trust and resilience. Naming emotions boosts emotional intelligence. Gratitude, conversation cards, and "Can I help?" transform parenting. TIMESTAMPS [00:00:00] Welcome to the Brave Table: Nadim Saad Introduction [00:02:00] Affirmation and Intentional Parenting [00:03:30] Raising Happy, Confident, and Successful Kids: Nadim's Journey [00:07:00] The Parenting Wake-Up Call: Lessons from the “1-2-3” Method [00:12:00] Giving Kids a Sense of Agency [00:19:00] How to Navigate Sibling Rivalry and Caregiver Differences [00:27:00] Breaking the Shame Cycle: Compassionate Parenting [00:36:00] Revolutionary Tools for Emotional Regulation [00:45:00] Introducing the 10 Powers for Kids [00:52:00] Spill the Chai: Nadim Gets Personal [00:55:00] Closing Thoughts: Parenting as Leadership To receive a free gift, email a screenshot of your 5-star review of The Brave Table to support@globalgrit.co

Finscale est aussi en vidéo sur Youtube : https://www.youtube.com/@finscale. Dans cet épisode, je reçois Nadim Takchi, un expert en immobilier et entrepreneur passionné qui évoque ses expériences dans le secteur immobilier, la blockchain et son engagement dans des projets au Liban. Nous parlons d'un sujet qui intéresse de plus en plus les investisseurs, celui de la démocratisation du PE immobilier, de l'accès aux fonds Tier 1 et des stratégies d'investissement dans un marché immobilier cyclique par nature. Nous parlons spécifiquement d'EQT et du déploiement de ce fonds en Europe. Nous parlons bien entendu de la création de la plateforme OpenStone. Il aborde l'évolution depuis le lancement, la structuration des fonds, le fonds de fonds, ainsi que les enjeux de liquidité et de performance. Nous parlons de l'importance de l'évangélisation du marché des actifs privés, de la conformité ESG, et des stratégies de distribution.Chapitres : 00:00 Introduction et parcours de Nadim Takchi05:47 Défis et apprentissages dans l'écosystème libanais11:47 Accès aux fonds internationaux et stratégies d'investissement18:08 Opportunités sur le marché immobilier européen23:55 Perspectives sur les marchés émergents et l'avenir des investissements29:54 Structuration des fonds d'investissement37:49 Conformité ESG et investissements responsables44:29 Intérêts des grands fonds sur le marché retailPour contacter Openstone : https://www.openstone.com/Pour contacter Nadim Takchi : https://www.linkedin.com/in/nadtakchi

The pod is back after a two-week break! Anthony is joined by Nour, Nadim, and Karine as they react to unhinged Israeli influencers. They also discuss Joy Tassidis' copycat, Anthony's beef with Lecico, Lonerbox using Anthony as clickbait, a bit of Ethan Klein, Political Pen's weird video with his sister, and a lot more!

Worship That Will CHANGE You | Jumuah Khutbah by Nadim BashirBecome a supporter of this podcast: https://www.spreaker.com/podcast/learn-about-islam--5484193/support.

Finscale est aussi en vidéo sur Youtube : https://www.youtube.com/@finscale. Il s'agit de l'extrait de l'épisode diffusé ce dimanche avec Nadim Takchi, co-fondateur d'Openstone.

En cette veille de Noël pour les chrétiens, reportage à Bethléem, en Cisjordanie occupée, où l'atmosphère n'est pas vraiment à la fête. La ville où, selon la croyance, Jésus serait né, est sinistrée depuis le début de la guerre entre Israël et le Hamas le 7 octobre 2023. Des hôtels fermés, faute de clients, quasiment aucun pèlerin, et une population locale qui sombre dans la pauvreté. De notre envoyé spécial à Bethléem,Devant la basilique de la Nativité, quelques pèlerins venus d'Asie, une dizaine tout au plus.Nadim tient une boutique de souvenirs transmise de génération en génération depuis 200 ans. « Cette année, Bethléem est triste ! Nous n'avons aucun touriste. Regardez, il n'y a même pas de décorations dans Bethléem. Ça ne ressemble vraiment pas à l'ambiance de Noël », se désole l'homme.Conséquence, sur les 80 hôtels que compte la ville, seuls 22 sont ouverts. Elais Arja dirige l'établissement Bethléem, presque désert. Il nous raconte le déclin des clients : « La crise a commencé avec le Covid, on a été fermé pendant deux ans. Puis, on a ouvert quelques mois seulement. Et depuis maintenant 445 jours et le début de la guerre, on a dû fermer à nouveau faute de visiteurs. J'ai 400 chambres à 50 dollars la nuit ici. Ça fait plus de 8 millions de pertes ! ».« Par rapport à une année normale, nous n'accueillons que 2% de touristes. Chaque jour, le manque à gagner est d'un million et demi de dollars pour la ville de Bethléem avec les hôtels, les restaurants, les souvenirs », s'inquiète Majed Israk, adjoint du ministre palestinien du Tourisme, qui nous raconte la situation catastrophique de l'économie du tourisme à Bethléem.« Un tiers des habitants de Bethléem n'a aucun revenu »Plus grave encore, des dizaines de milliers d'habitants se retrouvent sans travail. « 8 000 employés vivaient du tourisme, et plus de 10 000 travaillaient en Israël, dans le bâtiment notamment. Mais depuis le 7-Octobre, ils n'ont plus le droit de passer la frontière. Aujourd'hui, un tiers des habitants de Bethléem n'a aucun revenu ! », rajoute Majed Israk.Il suffit de se rendre au marché, à l'autre bout de la ville, pour percevoir cette pauvreté galopante. Mai y fait ses courses avec ses trois enfants.« Même les produits essentiels, il y en a beaucoup que je n'achète pas, car nous n'avons plus les moyens. Mon mari ne travaille plus depuis le début de la guerre. Il était employé en Israël », raconte la mère de famille.Alors à Bethléem, les initiatives se multiplient. Le père Laurent, membre de la communauté apostolique salésienne, est responsable d'une boulangerie solidaire. Il nous explique ce qui a changé : « Au début, la boulangerie a été créée pour les pauvres de la région de Bethléem, on aidait 50 familles. Mais depuis le début de la guerre, on aide entre 120 et 130 familles et on donne la moitié de notre pain aux bonnes œuvres. En échange de plusieurs pains par jour, les familles paient un montant symbolique comme 5 euros par mois ».Dans une rue près de la Nativité, un chrétien palestinien nous confie son vœu le plus cher pour Noël : « La paix, la paix, la paix, et encore la paix ! ».À lire aussiGaza: à Bethléem, un voile de tristesse enveloppe les célébrations de Noël 2023

The Sponsors We want to thank Underground Printing for starting this and making it possible—stop by and pick up some gear, check them out at ugpmichiganapparel.com, or check out our selection of shirts on the MGoBlogStore.com. And let's not forget our associate sponsors: Peak Wealth Management, Matt Demorest - Realtor and Lender, Champions Circle, Human Element, Ann Arbor Elder Law, Michigan Law Grad, Venue by 4M, Winewood Organics, Sharon's Heating & Air Conditioning, Royal Oath Insurance Group, Community Pest Solutions, Autograph: Fandom Rewarded, who just launched an app where you earn rewards for things like reading MGoBlog and listening to our podcast, and SignalWire where we are recording this. Featured Musician: Tree City THE VIDEO: [After THE JUMP: Things said.] --------------------- 1. Ohio State Preview: Offense starts at the top Is Howard any better than Kyle McCord? Because McCord was actually really good in The Game last year. How Chip Kelly is the running game? How Ryan Day are they on 3rd & 3? Injuries to the offensive line have drawn in a couple of guards who weren't expected to play yet, put Carson Hinzman back at C and kicked Donovan Jackson out to left tackle, but these are first-world problems. Jeremiah Smith's freshman eligibility is a global problem. Emeke Egbuka is a dangerous slot weapon that wasn't fully utilized until he got to play there. 2. Ohio State Preview: Defense starts at 18:02 They brought back almost everybody and added the #1 transfer in the portal, meaning 5-star Sonny Styles is now at WLB for new Bandit uber 5-star Caleb Downs. Not as relevant that you can block JT Tuimolaoau and Jack Sawyer and survive because Evan Link isn't blocking those guys. Lathan Ransom has been a superstar at Adjuster safety for them. Weakness is the cornerbacks get left in man and are not elite—a weakness that Michigan is in a particularly bad position to exploit. 3. Basketball vs Xavier and Virginia Tech starts at 35:17 They faced a switching team and switched Everything! On-ball defense was brilliant in both games. Coming from guys we expected and from guys we didn't expect. Offensively they can find a guy (Gayle vs VT, Wolf vs Xavier) to keep them going until they get good at their offense, but that's coming too and you can see it in Vlad's usage. Seth wants an NIL program to pay Vlad $1000 per dunk and subtract $100 for every shot missed at the rim that's not a dunk. 4. Recruiting starts at 54:36 Underwood's arm strength is THERE but he varies his angles and speed, and that's why there's a hitch. His movement is also THERE: breakaway speed to extend plays. Seth runs us through guys to pay attention to down the stretch. See you next time for our live Signing Day show. About the Featured Artist: Tree City I call them 7, 3, and 4. [photo: Benjamin Weatherston] Those of you who've been paying attention know we always have a little surprise for The Game, but this one surprised even me. Nadim got in touch with local legend/Michigan grad Evan Haywood just in time to get us a preview of Tree City's highly anticipated next album "Pure Levels." For those who are tapped into the Ann Arbor music scene, you're going "Holy shit they got a copy of Tree City's new album!???" (it won't be released until December 13). For the rest (vast majority) of you: Tree City is a hip-hop collective from Ann Arbor that formed in 2005 and quickly became an integral part of the local scene. Three original members remain: Haywood ("Clavius Crates"), Kyle Hunter ("Silas Green"), and Jacoby Simmons ("DJ Cataclysmic") along with Charles Cheek ("Cheeks"), who joined in 2008. It's a big deal because we haven't had a Tree City release since their critically acclaimed "Thus Far" back in 2010, meaning the entirety of the Hoke and Harbaugh eras went by with people wondering when these guys are going to make another. Haywood calls "Pure Levels" the… magnum opus of homegrown hip-hop, over a decade in the making. It promises to be the definitive statement from several of the finest lyricists ever to emerge from Michigan. Their sound is intellectual, futuristic, and—IMO—a little bit jazzy in the way they quote and reference. It's fun and danceable stuff, but the lyrics are the thing. If you like grounded philosophy in your hip-hop this is the hip-hop for you. Songs: Love Hotels (produced by Dykehouse) Story 2 Story (Dykehouse) Raspberry Balm (produced by Vulfpeck) Also because Across 110th Street will get our Youtubes taken down, the opener and outro: “The Employee is Not Afraid”—Bear vs. Shark “Ruska Vodka”—Motorboat

This week on the pod, Anthony is joined by Nour and Nadim as they discuss Twitch's stupid new policy around the word "zionist" and Ethan Klein's role in the matter. They're also ranking the best and worst Lebanese Hollywood celebs!

This week on the pod, Anthony, Nour, and Nadim discuss the election results, madness in Iran, and lots of crazy H3 vs Hasan updates!

5 Signs of a Hard Heart | Jumuah Khutbah by Nadim BashirBecome a supporter of this podcast: https://www.spreaker.com/podcast/learn-about-islam--5484193/support.

Lesley and Ben's season on International TV continues with MOBILE SUIT GUNDUM: WITCH FROM MARS with returning guest Jeff Martin. Jeff has been working on a new ttrpg project called BIG ROBOTS BIG FEELINGS and that means watching a lot of Gundum anime as research, alternating between Mobile Suit and Macross shows. Jeff's bringing that giant robot expertise to Syndicated! We talk about sad birthday songs, how storytelling pacing has changed over time, the history of mecha as a genre and werewolves. It's a wild one!We're watching Episode Zero, Prologue. At Folkvangr, a space based mobile suit laboratory base on the side of an asteroid, scientists and pilots are working tirelessly to bring a new type of mech suit online, one powered by the GUND format that will allow machines to interface directly with human brains. Meanwhile, two key crew members of the Folkvangr base, pilots Elnore Samaya and Nadim Samaya, struggle to raise their toddler, Ericht, on board the base. When a government takeover of the Gundam laboratory leads to its near destruction, only Elnore and Ericht survive, as Nadim dies fighting the armed intruders bent on purging the world of Gundams. Syndicated with Lesley and Ben is a twice monthly podcast about television, genre and storytelling in which your hosts watch one episode of a new show and explore the history of television one episode at a time. From family room sitcoms to space exploration shows, reality TV to procedurals and game shows, we're going to cover it all and give you the context you need to understand the wonderful world of television and the stories we love. Our current season is International TV. Our Logo is by Terra Bosart, the theme song is by Mandra Sigma and the show is edited by Jay Gagnon.

The Sponsors We want to thank Underground Printing for starting this and making it possible—stop by and pick up some gear, check them out at ugpmichiganapparel.com, or check out our selection of shirts on the MGoBlogStore.com. And let's not forget our associate sponsors: Peak Wealth Management, Matt Demorest - Realtor and Lender, Champions Circle, Human Element, Ann Arbor Elder Law, Michigan Law Grad, Venue by 4M, Winewood Organics, Sharon's Heating & Air Conditioning, Royal Oath Insurance Group, Autograph: Fandom Rewarded, who just launched an app where you earn rewards for things like reading MGoBlog and listening to our podcast, SignalWire where we are recording this, and introducing Community Pest Solutions. Featured Musician: Nadim Azzam The Video: [After THE JUMP: Things said.]  --------------------- 1. MSU Preview: Offense starts at the top MSU goes as Aidan Chiles, which is in all directions. Some of those interceptions are freshman; some are just really not accurate. They're bringing him along in an interesting way, which is max protection and letting him look downfield. He has a threat in Nick Marsh who's really emerging in the back half of the season. Other targets are just dudes. OL has some big issues on the right side, look cobbled together. Alarming how well they were able to run the ball consistently against Iowa. Michigan needs to keep Chiles in the pocket. 2. MSU Preview: Defense starts at 19:01 They're weak at defensive tackle but cover it up with their burly LBs playing downhill. Other than play-action pass, what can we do Alex? Probably need to get creative. Consider beefing up if they have Hinton back and can run out multiple OTs, but Evan Link as 7th OL? You don't have the dudes who are going to win those matchups as much anymore. They do give up a big long run per week so many we'll have a Mullings beastquake again. Or maybe just once we'll get an Edwards vs Cal Haladay throw. 3. Illinois After Review starts at 34:30 Brian is NOT as mad at Kirk Campbell as he was before going over the film. There were a lot of good ideas in there that his quarterback just couldn't execute. Offensive line seems to be coming together—Gentry was actually *Good*. Priebe is rounding into a 2nd team all-B10 kind of player. Crippen eh but not terrible. Persi might just be what he is. Tuttle was BAD. The overturned interception was to a guy covering grass—it's not even *at* a receiver. Defensively, yeah, don't put them in a terrible situation. Barham had a great game, they covered a lot of the weird stuff that Bielema dumped on them, but were constantly starting drives at midfield or in Michigan territory. Dammit Wink things have largely disappeared save for 2-minute drills, where they're rushing high and playing soft man. 4. Hoops vs Oakland, and Toledo Preview starts at 59:56 Exhibition showed what we wanted to see, which was not many bad shots against a tricky zone defense. The ball didn't stick: when you can see all of these former PGs together they can all get a little creative. It's not going to be no-turnover but they get very good shots, including free throws. About the Musical Artist: Nadim Azzam Says my friend Nadim Azzam, "You've got to hurt to heal." Through painfully honest self-reflection, Nadim Azzam addresses depression, addiction, and the dysfunctional realities of our times with his songs rooted in hope and connectivity. A Jewish Egyptian-Palestinian American born in Vermont, raised in Southeast Michigan and sent off to the Arizona desert, Nadim's life is hard to pin down - as is his music. A singer, rapper, and songwriter who makes his own beats and plays multiple instruments on his tracks, Nadim's new single "$20 Gold Piece" is out now. Nadim was voted Detroit's finalist in NPR's Tiny Desk Contest by WDET, performing at the Concert of Colors. He has opened for The Kid LAROI at Eastern Michigan University, Robert Glasper, Yebba,  Raheem DeVaughn and Bilal at the Aretha Franklin Amphitheatre. He has previously traveled the United States with Grammy-nominated reggae artist Matisyahu, on a unity tour to promote peace between Pro-Palestine and Pro-Israel students on American college campuses. Nadim's music video “The Come Up” won Best Hip-Hop/Rap Video and Audience Choice Award at the 2024 Michigan Music Video Awards. Mystery Offer: Ope, there's an Autograph Mystery Offer in this article. Click HERE to open and claim your prize. Song choices: $20 Gold Piece Revelations (LANDR gddt) Get the Money Also because Across 110th Street will get our Youtubes taken now now, the opener and outro: “The Employee is Not Afraid”—Bear vs. Shark “Ruska Vodka”—Motorboat

Like Two Wings of a Bird | Jumuah Khutbah by Nadim BashirBecome a supporter of this podcast: https://www.spreaker.com/podcast/learn-about-islam--5484193/support.

Anthony, Nour, and Nadim discuss some recent war developments and rank the best and worst emergency backpack items.

Living in a Corrupt World | Jumuah Khutbah by Nadim BashirBecome a supporter of this podcast: https://www.spreaker.com/podcast/learn-about-islam--5484193/support.

What does recent research say about the role of perirectal spacers in prostate cancer treatment? In this episode of the BackTable Urology Podcast, host Dr. Jose Silva discusses the use of perirectal spacers for prostate radiotherapy with guests Dr. Eric Chenven, Chief of Urology at Broward Health Medical Center, and Dr. Nadim Nasr, a radiation oncologist at Arlington Radiation Oncology. --- This podcast is supported by: Boston Scientific SpaceOAR Hydrogel https://www.spaceoar.com/about-spaceoar-hydrogel/how-spaceoar-hydrogel-works/?utm_source=google&utm_medium=cpc&utm_campaign=uro-ph-us-spaceoar-dtp&utm_content=nf-cs-prostatecancer_search_en_us_brand_conversion_dtp_uro-spaceoar-651995397243-res&gad_source=1&gclid=CjwKCAjw9eO3BhBNEiwAoc0-jTE63KEHSnZ1soXre9ovVRqweY2QctIuZ_iN2QUjk6Px4k6fK1757BoCVNgQAvD_BwE --- SYNPOSIS Their conversation delves into the use of Boston Scientific's SpaceOAR hydrogel to reduce radiation exposure to the rectum. The experts elaborate on the techniques and logistical challenges of placing spacers, as well as their effects on patient outcomes. They also discuss insurance hurdles, use of sedation, fiducial marker placement, and the impact of large prostate size on treatment efficacy. Finally, they touch on Barrigel, the newest spacer option. This episode emphasizes the need for collaboration between urologists and radiation oncologists to improve patient care. --- TIMESTAMPS 00:00 - Introduction 06:33 - Importance of Perirectal Spacing 11:17 - Techniques and Protocols 13:00 - Barrigel: The New Option 14:58 - Challenges and Practical Considerations 24:55 - Future Directions --- RESOURCES Boston Scientific SpaceOAR https://www.bostonscientific.com/en-US/products/hydrogel-spacers/spaceoar-hydrogel.html URO108 - Minimizing Radiation Therapy Side Effects https://www.backtable.com/shows/urology/podcasts/108/minimizing-radiation-therapy-side-effects URO123 - Perfecting Rectal Spacer Placement for Optimal Care https://www.backtable.com/shows/urology/podcasts/123/perfecting-rectal-spacer-placement-for-optimal-care

How to Avoid Being Misguided | Jumuah Khutbah by Nadim BashirBecome a supporter of this podcast: https://www.spreaker.com/podcast/learn-about-islam--5484193/support.

Israel isn't satisfied with genociding Palestinians in Gaza, so it has now set its sights on Lebanon. Anthony and Nadim react to their country being destroyed by the terrorist & genocidal entity known as Israel.

In this episode of The Garage we talk about vehicle batteries, battery technology and battery management, all critical topics for the shift to EV's. Our guest is Nadim Maluf, founder and CEO of Qnovo, a leader in battery software, who joins Sonatus CEO Dr. John Heinlein.

Har du varit med om en olycka, och lyckats ta dig tillbaka efter den? Hur finner du kraft när livet bär emot? Har du något mantra du brukar hämta kraft ifrån i svåra stunder? Lyssna på alla avsnitt i Sveriges Radio Play. När kvällens programledare, Nadim Ghazale, arbetade som polis hamnade han i en livsomvälvande trafikolycka. Under jakten på en förare som smitit från en trafikolycka krockade polisbilen med en lastbil. Nadim fick sin höft krossad. Det blev en lång och tuff resa tillbaka både mentalt och fysiskt för Nadim. I kvällens Karlavagnen vill vi veta hur du hittat tillbaka efter en svår upplevelse. Hur hittade du din kraft och styrka att återhämta dig? Ring in och berätta din historia. Kanske kan din erfarenhet inspirera andra att hitta sin väg tillbaka.Ring eller mejla oss, på karlavagnen@sverigesradio.se eller skriv till oss på Facebook och Instagram.

Sveriges största samtalsrum - där lyssnarnas berättelser är allt! Måndag-fredag & söndag 21:40 till midnatt. Ring 020-22 10 30. Lyssna på alla avsnitt i Sveriges Radio Play. När kvällens programledare Nadim Ghazale var sju år gammal flydde han från Libanon till Sverige. Sen dess har han fått hjälp av många människor som pekat honom i rätt riktning när han själv tagit tvivelaktiga beslut. Utan de människorna hade de kunnat gå illa för Nadim. I kvällens program pratar vi om förebilder och viktiga människor vi mött på vägen. Har du fått hjälp av någon? Eller är du kanske den som alltid hjälper? Ring eller mejla oss, på karlavagnen@sverigesradio.se eller skriv till oss på Facebook och Instagram.

Josh Sebo (COO of OfferVault), Adam Young (CEO of Ringba), industry legend Harrison Gevirtz and special guest Nadim Kuttab (Co-Founder of Xevio.io) discuss: - Deep Dive: Native Advertising - Paid Media - Taboola & Outbrain - Content & Creative Production - Media Buying - Advice for newbies working with Native Ads - Biggest mistakes you see being made related to Native Ads - Affiliate Summit 2024 & The Native Ads Panel Official Sponsor: CrakRevenue - (https://www.crakrevenue.com/the-affiliate-marketing-show/) Get your Free Copy of "The Pay Per Call Revolution" now! Just pay shipping and handling: - (https://www.paypercallrevolution.com) Follow Us: OfferVault: WEBSITE: https://www.offervault.com/ FACEBOOK: https://www.facebook.com/offervault INSTAGRAM: https://www.instagram.com/offervaultmarketing/ TWITTER: https://www.twitter.com/offervault LINKEDIN: https://www.linkedin.com/company/offer-vault/ Adam Young: RINGBA: https://www.ringba.com RINGBA's INNER CIRCLE: https://try.ringba.com/inner-circle/ FACEBOOK: https://www.facebook.com/ringba INSTAGRAM: https://www.instagram.com/adamyoung/ TWITTER: https://www.twitter.com/arbitrage LINKEDIN: https://www.linkedin.com/in/capitalist Harrison Gevirtz: INSTAGRAM: https://www.instagram.com/affiliate/ LINKEDIN: https://www.linkedin.com/in/harrisongevirtz/ Nadim Kuttab: XEVIO: https://xevio.io/ INSTAGRAM: https://www.instagram.com/the.native.guy_nadim/ LINKEDIN: https://www.linkedin.com/in/nadimkuttab/ LINKEDIN: https://www.linkedin.com/company/xevio/

A new Aesop store is opening in Patrick's neighborhood! But is it worth the price? Plus, a BONUS conversation at the end with sunscreen expert and organic chemist Dr. Nadim Shaath.Music: https://www.purple-planet.com

In Literary Optics: Staging the Collective in the Nahda (Syracuse UP, 2024), Maha AbdelMegeed offers a compelling and far-reaching alternative to the traditional mode of analyzing Arabic literature through an encounter between Arabic narrative forms and European ones. Drawing upon close engagements with the works of canonical authors from the period, including Hassan Husni al-Tuwayrani, Muhammad al-Muwaylihi, Ali Mubarak, Francis Marrash, and ‘Abdallah al-Nadim, AbdelMegeed addresses not where these works emanate from but rather how and why they were drawn together to form a canon. In doing so, she rejects the expectation that these texts, through the trope of encounter, hold the explanatory key to modern Arabic literature. In this reformulation of Arabic literary history, AbdelMegeed argues that the canon is forged through an urgency to define a new form of political sovereignty and to make history visible. In doing so, she explores three pivotal concepts: the spectral (khayal), the trace (athar) and the collective (alnās). By examining the texts through these concepts, Literary Optics provides a remarkable intellectual history that delves into the aesthetic, philosophical, and political stakes of nineteenth-century Arabic literature. Maha AbdelMegeed is assistant professor of modern Arabic literature at the American University of Beirut. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/new-books-network

In Literary Optics: Staging the Collective in the Nahda (Syracuse UP, 2024), Maha AbdelMegeed offers a compelling and far-reaching alternative to the traditional mode of analyzing Arabic literature through an encounter between Arabic narrative forms and European ones. Drawing upon close engagements with the works of canonical authors from the period, including Hassan Husni al-Tuwayrani, Muhammad al-Muwaylihi, Ali Mubarak, Francis Marrash, and ‘Abdallah al-Nadim, AbdelMegeed addresses not where these works emanate from but rather how and why they were drawn together to form a canon. In doing so, she rejects the expectation that these texts, through the trope of encounter, hold the explanatory key to modern Arabic literature. In this reformulation of Arabic literary history, AbdelMegeed argues that the canon is forged through an urgency to define a new form of political sovereignty and to make history visible. In doing so, she explores three pivotal concepts: the spectral (khayal), the trace (athar) and the collective (alnās). By examining the texts through these concepts, Literary Optics provides a remarkable intellectual history that delves into the aesthetic, philosophical, and political stakes of nineteenth-century Arabic literature. Maha AbdelMegeed is assistant professor of modern Arabic literature at the American University of Beirut. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/literary-studies

In Literary Optics: Staging the Collective in the Nahda (Syracuse UP, 2024), Maha AbdelMegeed offers a compelling and far-reaching alternative to the traditional mode of analyzing Arabic literature through an encounter between Arabic narrative forms and European ones. Drawing upon close engagements with the works of canonical authors from the period, including Hassan Husni al-Tuwayrani, Muhammad al-Muwaylihi, Ali Mubarak, Francis Marrash, and ‘Abdallah al-Nadim, AbdelMegeed addresses not where these works emanate from but rather how and why they were drawn together to form a canon. In doing so, she rejects the expectation that these texts, through the trope of encounter, hold the explanatory key to modern Arabic literature. In this reformulation of Arabic literary history, AbdelMegeed argues that the canon is forged through an urgency to define a new form of political sovereignty and to make history visible. In doing so, she explores three pivotal concepts: the spectral (khayal), the trace (athar) and the collective (alnās). By examining the texts through these concepts, Literary Optics provides a remarkable intellectual history that delves into the aesthetic, philosophical, and political stakes of nineteenth-century Arabic literature. Maha AbdelMegeed is assistant professor of modern Arabic literature at the American University of Beirut. Learn more about your ad choices. Visit megaphone.fm/adchoices Support our show by becoming a premium member! https://newbooksnetwork.supportingcast.fm/middle-eastern-studies

Doctors Vamsi Velcheti, Sandip Patel, and Michael Zervos discuss recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for patients and the role of surgery in the era of targeted therapy and immuno-oncology in lung cancer. TRANSCRIPT Dr. Vamsi Velcheti: Hello, I'm Dr. Vamsi Velcheti, your guest host for the ASCO Daily News Podcast today. I am a professor of medicine and director of thoracic medical oncology at the Perlmutter Cancer Center at NYU Langone Health. On today's episode, we'll be discussing recent updates on the management of early-stage non-small cell lung cancer (NSCLC), including the optimization of neoadjuvant and adjuvant treatment options for our patients, and the evolving role of surgery in the era of targeted therapy and immuno-oncology in lung cancer.  Today, I am delighted to be joined by two renowned experts in this space, Dr. Sandip Patel and Dr. Michael Zervos. Dr. Patel is a professor of medicine and a medical oncologist specializing in lung cancer at UCSD. Dr. Mike Zervos is the clinical chief of the Division of Robotic Thoracic Surgery and Director of General Thoracic Surgery at NYU Langone. Our full disclosures are available in the transcript of this episode, and disclosures relating to all episodes of the podcast are available at asco.org/DNpod. Dr. Patel and Dr. Zervos, it's a great honor to have you on the podcast today. Welcome aboard. Dr. Sandip Patel: Great to be joining you.  Dr. Vamsi Velcheti:  Let's get started with Dr. Patel. As you know, over the last decade we've had dramatic advances in systemic therapy options for patients with metastatic non-small cell lung cancer, in both the realms of targeted therapy and immunotherapy. These have significantly improved outcomes for our patients with metastatic lung cancer. What's exciting is that more recently, we've seen the incorporation of these agents, both targeted therapies and immunotherapies, in early-stage non-small cell lung cancer. Dr. Patel, can you tell our listeners about these exciting recent advances and why do you think it's so important to incorporate these personalized systemic therapy options for our early-stage patients? Dr. Sandip Patel: I think it's a great point and a great question. And so, I think one thing to understand is that non-small cell lung cancer is actually multiple diseases. We give it one name based on how it looks under the microscope, but the vast majority of our advances to improve outcomes for patients have come from our ability to understand specific subgroups.  Many of our therapies have had activity in the advanced setting. We have our patients with metastatic or more widespread disease, which naturally led to the thought that could we utilize these therapies in earlier stage disease and potentially increase the rate of cure for many of our patients, lung cancer being the most common cancer killer worldwide. And so to your point, trying to understand how to best treat a patient really involves personalized medicine, typically driven by understanding the genomic profile of their tumor and two of the genes that have graduated from being tested for in the metastatic setting and now in the localized setting are EGFR and ALK. And these in particular are mutations that confer sensitivity to small molecule inhibitors, EGFR with osimertinib, ALK in the localized setting with alectinib based on the data that we've seen.  And so, one of the areas that's been particularly exciting is our ability to maximize a patient's chance for durable remissions by integrating these therapies after surgery, after chemotherapy when appropriate, and continuing generally for a finite amount of time, two to three years depending on the agent in the study we're discussing for these patients. Additionally, immunotherapy, which has revolutionized our treatment of patients with metastatic disease, may be particularly well-suited for the localized setting of non-small cell lung cancer as well. Dr. Vamsi Velcheti: Excellent points, Sandip. You're absolutely right, in the metastatic setting, we've all come to accept molecular testing, sequencing, and biomarker profiling as a standard, but unfortunately, that hasn't quite yet percolated into the early-stage setting. Can you talk about some of the challenges that we face as we have these therapeutic options available now for more early-stage patients? Dr. Sandip Patel: So, I think there are 3 flavors of localized therapy in non-small cell lung cancer. One is the advanced, unresectable stage 3, for which the approach is often concurrent chemo-radiation followed by some form of consolidated therapy. We're about to hear the results of LAURA, which is the study looking at EGFR-mutated non-small cell lung cancer.  For other patients, historically, the treatment has been durvalumab, an anti-PD-L1 directed immunotherapy. The other two are operative treatment of localized cancer: adjuvant treatment after surgery, or neoadjuvant or perioperative, in which chemoimmunotherapy begins before surgery. And testing depends on the settings. For the stage 3 patient who's likely getting concurrent chemo-radiation, they may have a very small amount of tissue, and so often these are done by pulmonary EBUS biopsies and that's how we pathologically confirm that advanced stage 3B. There may not be a lot of tissue available for molecular testing. In fact, if you look at the PACIFIC analysis, just looking at PD-L1, which is just an IHC off a single slide, a third of patients weren't able to even get a PD-L1, let alone a genomic result. And so, I think that's one of the areas of LAURA that's going to be particularly interesting to see as we try to implement it into our practice after seeing the full data.  I think in the adjuvant setting, we're lucky because our surgeons, Dr. Mike Zervos here, will get us a large amount of tissue in the surgical resection specimen, so we tend to get enough tissue to do genomics while they're under chemotherapy, there tends to be time to wait for their genomic result. Where this really gets complicated is in the neoadjuvant or perioperative setting, where time is everything.  The most important thing we can do for a patient in the localized space is get them to the operating room, get them started on radiation, their curative local modality, and that's where we have a time pressure but also a sample pressure because that is a diagnostic biopsy. It's a very small piece of tissue. Initially, there are multiple stains that have to be done to identify this lung cancer as opposed to another tumor. And so that's an area that I think we're going to need additional approaches given that cell-free DNA tends to have lower yield in lower stage disease in giving us a result. Dr. Vamsi Velcheti: Great points, Sandip. How do you deal with this issue in San Diego? The challenge is now we have a lot of trials, we'll talk about those neoadjuvant immunotherapy trials, but we know that immunotherapy may not be as effective in all patients, especially those with EGFR or ALK or some of these non-smoker, oncogene-driven tumors. So, we don't want to be giving patients treatments that may not necessarily be effective in the neoadjuvant space, especially when there is a time crunch, and we want to get them to surgery and all the complications that come with giving them targeted therapy post-IO with potential risk for adverse events. Dr. Sandip Patel: Absolutely. It is a great point. And so, the multidisciplinary team approach is key, and having a close relationship with the interventional pulmonary oncs, interventional radiology surgery, and radiation oncology to ensure that we get the best treatment for our patients. With the molecularly guided therapies, they are currently more on the adjuvant setting in terms of actually treating. But as you mentioned, when we're making a decision around neoadjuvant or perioperative chemo IO, it's actually the absence of EGFR now that we're looking for because our intervention at the current time is to give chemoimmunotherapy. Going back to the future, we used to use single gene EGFR within 24 hours, which was insufficient for a metastatic panel, but it often required five slides of tissue input. ALK can be done by IHC, and so some of these ‘oldie but goodie' pathologic techniques, and that pathologists, if I haven't emphasized, understanding what we're trying to do at a different context is so key because they are the ones who really hold the result. In the neoadjuvant and perioperative setting, which many of us favor, especially for stage 3A and stage 2B disease, understanding how we can get that result so that we can get the patient to the operating room in an expeditious way is so important. There is a time pressure that we always had in the metastatic setting, but I think we feel much more acutely in the neoadjuvant and perioperative setting in my opinion. Dr. Vamsi Velcheti: Fascinating insights, Dr. Patel.  Turning to Dr. Zervos, from a surgical perspective, there has been an evolution in terms of minimally invasive techniques, robotic approaches, and enhanced recovery protocols, significantly improving outcomes in our patients post-surgery. How do you see the role of surgery evolving, especially with the increasing complexity and efficacy of these systemic therapies? How do you envision the role of surgery in managing these early-stage patients, and what are the key considerations for surgeons in this new era? Dr. Michael Zervos: Thanks, Vamsi. Thanks, Sandip. Thank you for having me on the podcast. Obviously, it's an honor to be a part of such a high-level discussion. I have to say, from a surgeon's perspective, we often listen to you guys talk and realize that there's been a lot of change in this landscape. And I think the thing that I've seen is that the paradigm here has also changed. If we were having this discussion 10 years ago, a lot of the patients that I am operating on now, I would not be operating on. It really has been amazing. And I think the thing that stands out to me the most is how all of this has changed with neoadjuvant chemotherapy checkpoint inhibition. I think, for us as surgeons, that's really been the key. Whether it's CheckMate 816 or whatever you're following, like PACIFIC, the data supports this. And I think what we're seeing is that we're able to do the surgery, we're able to do it safely, and I think that the resectability rates are definitely high up there in the 90% range. And what we're seeing is pretty significant pathologic responses, which I think is really amazing to me.  We're also seeing that this has now shifted over to the oligometastatic realm, and a lot of those patients are also being treated similarly and then getting surgery, which is something that we would not have even thought of ever. When you look at the trials, I think a lot of the surgery, up to this point, has been done more traditionally. There's a specific reason why that happens, specifically, more through thoracotomy, less with VATS, and less with robotic. Sandip, I think you guys have a pretty robust robotic program at UCSD, so I'm sure you're pretty used to seeing that.   As you guys have become so much more sophisticated with the treatments, we have also had to modify what we do operatively to be able to step up to the plate and accept that challenge. But what we are seeing is yes, these treatments work, but the surgeries are slightly more complicated. And when I say slightly, I'm minimizing that a little bit.  And what's complicated about it is that the treatment effect is that the chemo-immune check inhibition actually has a significant response to the tumor antigen, which is the tumor. So it's going to necrose it, it's going to fibrose it, and wherever there is a tumor, that response on the surgical baseline level is going to be significant. In other words, there are going to be lymph nodes that are stuck to the pulmonary artery, lymph nodes that are stuck to the airway, and we've had to modify our approaches to be able to address that.   Now, fortunately, we've been able to innovate and use the existing technology to our advantage. Personally, I think robotics is the way we have progressed with all this, and we are doing these surgeries robotically, mainly because I think it is allowing us, not only to visualize things better, but to have sort of a better understanding of what we're looking at. And for that matter, we are able to do a better lymph node dissection, which is usually the key with a lot of these more complicated surgeries, and then really venturing out into more complicated things, like controlling the pulmonary artery. How do we address all this without having significant complications or injuries during the surgery? Getting these patients through after they've successfully completed their neoadjuvant treatment, getting them to surgery, doing the surgery successfully, and hopefully, with minimal to no morbidity, because at the end, they may be going on to further adjuvant treatment. All of these things I think are super important. I think although it has changed the landscape of how we think of things, it has made it slightly more complicated, but we are up for the challenge. I am definitely excited about all of this. Dr. Vamsi Velcheti: For some reason, like medical oncologists, we only get fixated on the drugs and how much better we're doing, but we don't really talk much about the advances in surgery and the advances in terms of outcomes, like post-op mortality has gone down significantly, especially in larger tertiary care centers. So, our way of thinking, traditionally, the whole intergroup trials, the whole paradigm of pneumonectomies being bad and bad outcomes overall, I think we can't judge and decide on current treatment standards based on surgical standards from decades ago. And I think that's really important to recognize.  Dr. Michael Zervos: All of this stuff has really changed over the past 10 years, and I think technology has helped us evolve over time. And as the science has evolved for you with the clinical trials, the technology has evolved for us to be able to compensate for that and to be able to deal with that. The data is real for this. Personally, what I'm seeing is that the data is better for this than it was for the old intergroup trials. We're able to do the surgery in a better, more efficient, and safer way. The majority of these surgeries for this are not going to be pneumonectomies, they are going to be mostly lobectomies. I think that makes sense. I think for the surgeons who might be listening, it doesn't really matter how you're actually doing these operations. I think if you don't have a very extensive minimally invasive or robotic experience, doing the surgery as open is fine, as long as you're doing the surgery safely and doing it to the standard that you might expect with complete lymph node clearance, mediastinal lymph node clearance, and intrapulmonary lymph node clearance. Really, I think that's where we have to sort of drive home the point, really less about the actual approach, even though our bias is to do it robotically because we feel it's less morbidity for the patient. The patients will recover faster from the treatment and then be able to go on to the next phase treatments. Dr. Vamsi Velcheti: In some of the pre-operative trials, the neoadjuvant trials, there have been some concerns raised about 20% of patients not being able to make it to surgery after induction chemo immunotherapy. Can you comment on that, and why do you think that is the case, Sandip?  Dr. Sandip Patel: Well, I think there are multiple reasons. If you look, about half due to progression of disease, which they might not have been great operative candidates to begin with, because they would have early progression afterwards. And some small minority in a given study, maybe 1% to 2%, it's an immune-related adverse event that's severe. So, it's something that we definitely need to think about. The flip side of that coin, only about 2 in 3 patients get adjuvant therapy, whether it be chemotherapy, immunotherapy, or targeted therapy. And so, our goal is to deliver a full multimodal package, where, of course, the local therapy is hugely important, but also many of these other molecular or immunologically guided agents have a substantial impact.  And I do think the point around neoadjuvant and perioperative is well taken. I think this is a discussion we have to have with our patients. I think, in particular, when you look at higher stage disease, like stage 3A, for example, the risk-benefit calculus of giving therapy upfront given the really phenomenal outcomes we have seen, really frankly starting with the NADIM study, CheckMate816, now moving on into studies like KEYNOTE-671, AEGEAN, it really opens your eyes in stage 3. Now, for someone who's stage 1/1b, is this a patient who's eager to get a tumor out? Is there as much of an impact when we give neoadjuvant therapy, especially if they're not going to respond and may progress from stage 1 and beyond? I think that's a reasonable concern. How to handle stage II is very heterogeneous. I think two points that kind of happen as you give neoadjuvant therapy, especially chemo-IO that I think is worth for folks to understand and this goes to Mike's earlier point, that is this concept if they do get a scan during your neoadjuvant chemo immunotherapy, there is a chance of that nodal flare, where the lymph nodes actually look worse and look like their disease is progressing. Their primary tumor may be smaller or maybe the same. But when we actually go to the OR, those lymph nodes are chock-full of immune cells. There's actually no cancer in those lymph nodes. And so that's a bit of a red herring to watch out for.   And so, I think as we're learning together how to deliver these therapies, because the curative-intent modality is, in my opinion, a local modality. It's what Mike does in the OR, my colleagues here do in the OR. My goal is to maximize the chance of that or really maximize the long-term cure rates. And we know, even as long as the surgery can go, if only 2 or 3 patients are going to get adjuvant therapy then 1 in 10, of which half of those or 1 in 20, are not getting the surgery and that's, of course, a big problem. It's a concern. I think better selecting towards those patients and thinking about how to make these choices is going to be hugely important as we go over. Because in a clinical trial, it's a very selective population. A real-world use of these treatments is different. I think one cautionary tale is that we don't have an approval for the use of neoadjuvant or perioperative therapy for conversion therapy, meaning, someone who's “borderline resectable.” At the time at which you meet the patient, they will be resectable at that moment. That's where our best evidence is, at the current time, for neoadjuvant or perioperative approaches.  Dr. Vamsi Velcheti:   I think the other major issue is like the optimal sequencing of immune checkpoint here. Obviously, at this point, we have multiple different trial readouts, and there are some options that patients can have just neoadjuvant without any adjuvant. Still, we have to figure out how to de-escalate post-surgery immunotherapy interventions. And I think there's a lot of work that needs to be done, and you're certainly involved in some of those exciting clinical trials. What do you do right now in your current clinical practice when you have patients who have a complete pathologic response to neoadjuvant immunotherapy? What is the discussion you have with your patients at that point? Do they need more immunotherapy, or are you ready to de-escalate?  Dr. Sandip Patel: I think MRD-based technologies, cell-free DNA technologies will hopefully help us guide this. Right now, we are flying blind along two axes. One is we don't actually know the contribution of the post-operative component for patients who get preoperative chemo-IO. And so this is actually going to be an ongoing discussion. And for a patient with a pCR, we know the outcomes are really quite good based on CheckMate816, which is a pure neoadjuvant or front-end only approach. Where I actually struggle is where patients who maybe have 50% tumor killing. If a patient has only 10% tumor killing ... the analogy I think in clinic is a traffic light, so the green light if you got a pCR, a yellow light if you have that anywhere from 20%-70% residual viable tumor, and then anything greater than that, you didn't get that much with chemo-IO and you're wondering if getting more chemo-IO, what would that actually do? It's a bit of a red light. And I'm curious, we don't have any data, but my guess would be the benefit of the post-op IO is because patients are in that kind of yellow light zone. So maybe a couple more cycles, we'll get them an even more durable response. But I am curious if we're going to start relying more on MRD-based technologies to define treatment duration. But I think it's a very complicated problem. I think folks want to balance toxicity, both medical and financial, with delivering a curative-intent therapy. And I am curious if this maybe, as we're looking at some of the data, some of the reasons around preferring a perioperative approach where you scale it back, as opposed to a neoadjuvant-only approach where there's not a clean way to add on therapy, if you think that makes sense. But it's probably the most complicated discussions we have in clinic and the discussion around a non-pCR. And frankly, even the tumor board discussions around localized non-small cell lung cancer have gone very complex, for the benefit of our patients, though we just don't have clean data to say this is the right path.   Dr. Vamsi Velcheti: I think that the need for a really true multidisciplinary approach and discussing these patients in the tumor board has never been more significant. Large academic centers, we have the luxury of having all the expertise on hand. How do we scale this approach to the broader community is a big challenge, I think, especially in early-stage patients. Of course, not everyone can travel to Dr. Zervos or you for care at a large tertiary cancer centers. So, I think there needs to be a lot of effort in terms of trying to educate community surgeons, community oncologists on managing these patients. I think it's going to be a challenge. Dr. Michael Zervos: If I could just add one thing here, and I completely agree with everything that has been said. I think the challenge is knowing beforehand. Could you predict which patients are going to have a complete response? And for that matter, say, “Okay. Well, this one has a complete response. Do we necessarily need to operate on this patient?” And that's really the big question that I add. I personally have seen some complete response, but what I'm mostly seeing is major pathologic response, not necessarily CR, but we are seeing more and more CR, I do have to say. The question is how are you going to predict that? Is looking for minimal residual disease after treatment going to be the way to do that? If you guys could speak to that, I think that is just tremendously interesting.  Dr. Vamsi Velcheti: I think as Sandip said, MRD is looking very promising, but I just want to caution that it's not ready for primetime clinical decision making yet. I am really excited about the MRD approach of selecting patients for de-escalation or escalation and surgery or no surgery. I think this is probably not quite there yet in terms of surgery or no surgery decision. Especially for patients who have early-stage cancer, we talk about curative-intent treatment here and surgery is a curative treatment, and not going to surgery is going to be a heavy lift. And I don't think we're anywhere close to that. Yet, I'm glad that we are having those discussions, but I think it may be too hard at this point based on the available technologies to kind of predict CR. We're not there.  Dr. Michael Zervos: Can I ask you guys what your thought process is for evaluating the patient? So, when you're actually thinking about, “Hey, this patient actually had a good response. I'm going to ask the surgeons to come and take a look at this.” What imaging studies are you actually using? Are you just using strictly CT or are you looking for the PET? Should we also be thinking about restaging a lot of these patients? Because obviously, one of the things that I hate as a surgeon is getting into the operating room only to find out that I have multiple nodal stations that are positive. Which really, in my opinion, that's sort of a red flag. And for me, if I have that, I'm thinking more along the lines of not completing that surgery because I'm concerned about not being able to provide an R0 resection or even having surgical staple lines within proximity of cancer, which is not going to be good. It's going to be fraught with complications.  So, a lot of the things that we as surgeons struggle with have to do with this. Personally, I like to evaluate the patients with an IV intravenous CT scan to get a better idea of the nodal involvement, proximity to major blood vessels, and potentially even a PET scan. And though I think in this day and age, a lot of the patients will get the PET beforehand, not necessarily get it approved afterwards. So that's a challenge. And then the one thing I do have to say that I definitely have found helpful is, if there's any question, doing the restaging or the re-EBUS at that point to be particularly helpful.  Dr. Sandip Patel: Yeah, I would concur that having that pathologic nodal assessment is probably one of the most important things we can do for our patients. For a patient with multinodal positive disease, the honest truth is that at our tumor board, that patient is probably going to get definitive chemoradiation followed by their immunotherapy, or potentially soon, if they have an EGFR mutation, osimertinib. For those patients who are clean in the mediastinum and then potentially have nodal flare, oftentimes what our surgeons will do as the first stage of the operation, they'll actually have the EBUS repeated during that same anesthesia session and then go straight into surgery. And so far the vast majority of those patients have proceeded to go to surgery because all we found are immune cells in those lymph nodes.  So, I think it's a great point that it's really the pathologic staging that's driving this and having a close relationship with our pathologists is key. But I think one point that I think we all could agree on is the way that we're going to find more of these patients to help and cure with these therapies is through improved utilization of low-dose CT screening in the appropriate population in primary care. And so, getting buy-in from our primary care doctors so that they can do the appropriate low-dose CT screening along with smoking cessation, and find these patients so that we can offer them these therapies, I think is something that we really, as a community, need to advocate on. Because a lot of what we do with next-generation therapies, at least on the medical oncology side, is kind of preaching to the choir. But getting the buy-in so we can find more of these cases at stage 1, 2 or 3, as opposed to stage 4, I think, is one of the ways we can really make a positive impact for patients. Dr. Vamsi Velcheti: I just want to go back to Mike's point about the nodal, especially for those with nodal multistation disease. In my opinion, those anatomic unresectability is a moving target, especially with evolving, improving systemic therapy options. The utilization for chemo radiation has actually gone down. I think that's a different clinical subgroup that we need to kind of think differently in terms of how we do the next iteration or generation of clinical trials, are they really benefiting from chemo-IO induction? And maybe we can get a subset of those patients in surgery. I personally think surgery is probably a more optimal, higher yield to potentially cure these patients versus chemo radiation. But I think how we identify those patients is a big challenge. And maybe we should do a sequential approach induction chemo-IO with the intent to kind of restage them for surgery. And if they don't, they go to chemo consolidation radiation, I guess. So, I think we need to rethink our approach to those anatomically unresectable stage 3s. But I think it's fascinating that we're having these discussions. You know, we've come to accept chemo radiation as a gold standard, but now we're kind of challenging those assumptions, and I think that means we're really doing well in terms of systemic therapy options for our patients to drive increased cures for these patients. Dr. Michael Zervos: I think from my perspective as a surgeon, if I'm looking at a CT scan and trying to evaluate whether a patient is resectable or not, one of the things that I'm looking for is the extent of the tumor, proximity to mediastinal invasion, lymph nodes size. But if that particular patient is resectable upfront, then usually, that patient that receives induction chemo checkpoint inhibition is going to be resectable afterwards. The ones that are harder are the ones that are borderline resectable upfront or not resectable. And then you're trying to figure out on the back end whether you can actually do the surgery.  Fortunately, we're not really taking many patients to the operating room under those circumstances to find that they're not resectable. Having said that, I did have one of those cases recently where I got in there and there were multiple lymph node stations that were positive. And I have to say that the CT really underestimated the extent of disease that I saw in the operating room. So, there are some challenges surrounding all of these things. Dr. Sandip Patel: Absolutely. And I think for those patients, if upfront identification by EBUS showed multi nodal involvement, we've had excellent outcomes by working with radiation oncologists using modern radiotherapy techniques, with concurrent chemo radiation, followed by their immunotherapy, more targeted therapy, at least it looks like soon. I think finding the right path for the patient is so key, and I think getting that mediastinal pathologic assessment, as opposed to just guessing based on what the PET CT looks like, is so important. If you look at some of the series, 8% to 10% of patients will get a false-positive PET on their mediastinal lymph nodes due to coccidioidomycosis or sarcoidosis or various other things. And the flip side is there's a false-negative rate as well. I think Mike summarized that as well, so I think imaging is helpful, but for me, imaging is really just pointing the target at where we need to get pathologic sampling, most commonly by EBUS. And getting our interventional pulmonary colleagues to help us do that, I think is so important because we have really nice therapeutic options, whether it's curative-intent surgery, curative-intent chemo radiation, where we as medical oncologists can really contribute to that curative-intent local therapy, in my opinion.  Dr. Vamsi Velcheti: Thank you so much Sandip and Mike, it's been an amazing and insightful discussion, with a really dynamic interplay between systemic therapy and surgical innovations. These are really exciting times for our patients and for us. Thank you so much for sharing your expertise and insights with us today on the ASCO Daily News Podcast.   I want to also thank our listeners today for your time. If you value the insights that you hear today, please take a moment to rate, review, and subscribe to the podcast wherever you get your podcasts. Thank you so much. [FH1]   Dr. Sandip Patel: Thank you. Dr. Michael Zervos: Thank you.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Follow today's speakers: Dr. Vamsidhar Velcheti @VamsiVelcheti Dr. Sandip Patel @PatelOncology Dr. Michael Zervos   Follow ASCO on social media: @ASCO on X (formerly Twitter) ASCO on Facebook ASCO on LinkedIn   Disclosures:  Dr. Vamsidhar Velcheti: Honoraria: ITeos Therapeutics Consulting or Advisory Role: Bristol-Myers Squibb, Merck, Foundation Medicine, AstraZeneca/MedImmune, Novartis, Lilly, EMD Serono, GSK, Amgen, Elevation Oncology, Taiho Oncology, Merus Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline   Dr. Sandip Patel: Consulting or Advisory Role: Lilly, Novartis, Bristol-Myers Squibb, AstraZeneca/MedImmune, Nektar, Compugen, Illumina, Amgen, Certis, Eli Lilly, Roche/Genentech, Merck, Pfizer, Tempus, Iovance Biotherapeutics. Speakers' Bureau: Merck, Boehringer Ingelheim Research Funding (Inst.):Rubius, Bristol-Myers Squibb, Pfizer, Roche/Genentech, Amgen AstraZenece/MedImmune, Fate, Merck, Iovance, Takeda   Dr. Michael Zervos: No relationships to disclose

This week on the pod, Anthony, Nadim, and Karine discuss the WW3 that almost happened, Wajih Sakr ghosting Anthony, and Joseph Merheb saving an injured fox. They're also finally ending the Bertilicious saga for good and discussing Dr. Food training his baby to review food. To cap it off, they're discussing the messed up Maria Cataleya family vlogging account, and a lot more!

This week on the pod, Anthony, Nour, and Nadim discuss important Crepaway-Bertilicious updates and Sarde After Dinner's recent burnout video. They're also reacting to Abou Hady's new tiktok content, a creepy Chantal Goya video, Joy Tassidis, Wajih Sakr's new WhatsApp revolution, and a lot more!

How can art complicate claims of progress, innovation and the use of rapidly developing emerging technologies in MENA? In this episode, Cima Chehab speaks to visual artist Nadim Choufi about how he incorporates technology into his artwork both as subject matter and as medium. In the conversation, they discuss Nadim's own artistic practice, his use of “lecture performances” and the question of whether life is truly enhanced by progress and technology, which is one of the main questions that underpins his work. Nadim also explores emerging art in the Middle East and how technology has transformed a new generation of artists – from digital illustrations to meme accounts. Nadim is a visual artist living in Beirut. He primarily focuses on the material histories and futures of innovation and desire, their social and political driving forces, and the visual and literary practices that surround them. He is a 2024 resident at the Jan van Eyck Academy. Currently he is the curator of the film programme of the 2024 festival edition of transmediale and a researcher at Haven For Artists. Previously he was co-Programs Director at Beirut Art Center. https://nadimchoufi.com/

This week on the pod, Anthony, Elijah, Nour, and Nadim are discussing Motaz's "cancelation", a man and his goat, Dr. Food's nasty new cakes, and TikTok getting banned in the US. They're also saying an emotional goodbye to Cocky!

In this bonus episode of Battle Lines, Senior Foreign Correspondent Sophia Yan speaks to two friends, Adam Ben-Shabbat and Nadim Tali, who grew up in a village known as the 'Oasis of Peace'. This village, situated between Tel Aviv and Jerusalem, is the only village in Israel where Palestinians and Jewish Israelis choose to live together. Adam and Nadim's friendship faced challenges after Adam decided to join the Israel Defence Force as a reservist in the wake of the October 7th attacks. Nadim meanwhile has had family members killed in Gaza. Despite the tensions, Adam and Nadim remain close friends.Contributors:Sophia Yan (Senior Foreign Correspondent). @sophia_yan on X.ReadDispatch: Inside the only place in Israel where Jews and Arabs choose to live together by Sophia Yan Hosted on Acast. See acast.com/privacy for more information.